Press "esc" to clear
Go to Advanced Search
Showing results 1120 of 1445
ActiniumpatientatUniversityHospitalHeidelberg_usagerequiresimagecredit.jpg

Article ID: 701174

TRIUMF and CNL Form Strategic Partnership to Enable Ground-Breaking Cancer Treatment

TRIUMF

TRIUMF, Canada’s particle accelerator centre, and Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology organization, are pleased to announce that they have agreed to pursue a strategic partnership around the commercial production of Actinium-225, a rare medical isotope that has the potential to serve as the basis of new ground-breaking cancer treatments.

Released:
27-Sep-2018 9:30 AM EDT

Article ID: 700814

B-Line Medical Celebrates International Healthcare Simulation Week

B-Line Medical

B-Line Medical®, an industry leader in video-driven healthcare education and outcome improvement, is excited to celebrate International Healthcare Simulation Week with the Society for Simulation in Healthcare.

Released:
20-Sep-2018 8:00 AM EDT

Article ID: 700279

Genesys Spine Releases AIS-C Stand-Alone System

Genesys Spine

Genesys Spine is pleased to announce the FDA clearance of our latest product line, the AIS-C Stand-Alone System.

Released:
10-Sep-2018 4:05 PM EDT
Smiling-Students_Kenya-1260x649-980x505.jpg

Article ID: 700263

DREAMS: A P3 Partnership

University of Virginia Darden School of Business

The DREAMS public-private partnership helps girls develop into Determined, Resilient, Empowered, AIDS-free, Mentored and Safe women. DREAMS utilizes a multisector approach to reduce HIV infections among adolescent girls and young women in 10 sub-Saharan African countries.

Released:
10-Sep-2018 1:05 PM EDT

Law and Public Policy

29DSC_6753UCSanDiegoPublicationsErikJepsenLG.jpg
  • Embargo expired:
    5-Sep-2018 8:00 AM EDT

Article ID: 699927

UC San Diego and Deerfield Management Create Poseidon Innovation to Advance Disease-Curing Therapeutics

University of California San Diego

University of California San Diego and Deerfield Management announce today the creation of Poseidon Innovation, LLC to advance disease-curing therapeutics. Through Deerfield’s $65-million commitment in Poseidon, UC San Diego investigators will have the funding and support to weather risky early-stage processes and expedite the drug-development cycle, allowing patients to receive treatment faster.

Released:
4-Sep-2018 1:15 PM EDT

Education

jared_elliot_nyc_demo_day_oct_2017.jpeg

Article ID: 699706

ORNL researchers enable real-time forensic analysis with new cybersecurity tool

Oak Ridge National Laboratory

Researchers at ORNL have developed a new cybersecurity tool called Akatosh that automates the process of analyzing computer networks to detect malware. The tool collects historical information on host systems on the network to immediately show changes that transpired leading up to and during a cyber attack, which saves precious time and resources previously spent manually searching the network for changes.

Released:
29-Aug-2018 10:30 AM EDT

Article ID: 699644

Wolters Kluwer and the Family Physicians Inquiries Network Enter Publishing Partnership

Wolters Kluwer Health: Lippincott Williams and Wilkins

Wolters Kluwer Health announced today it will begin electronic publishing of Evidence-Based Practice, the official journal of the Family Physicians Inquiries Network (FPIN). The monthly journal, which focuses on topics relevant to the daily practice of family medicine, will be curated in the Lippincott portfolio beginning in September 2018.

Released:
28-Aug-2018 11:05 AM EDT

Article ID: 699169

UChicago Medicine, Humana Sign Value-Based Care Agreement to Offer Enhanced Patient Experience for Humana Medicare Advantage Members

University of Chicago Medical Center

The University of Chicago Medicine and Humana Inc. have entered into a value-based agreement designed to offer a coordinated, patient-centered experience to help Humana Medicare Advantage members achieve their best health.

Released:
23-Aug-2018 11:00 AM EDT

Article ID: 699426

Dthera Sciences Receives FDA Breakthrough Device Designation For Its Alzheimer's Focused Development-Stage Product "DTHR-ALZ"

Dthera Sciences

Dthera™ Sciences (OTCQB:DTHR), the leading digital therapeutic company focusing on the elderly and individuals with neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to the Company's development-stage product, DTHR-ALZ.

Released:
23-Aug-2018 10:40 AM EDT

Showing results 1120 of 1445

Chat now!